Robert Busch

Robert Busch

Auto-generated profile, based on publicly available information

Robert Busch

Department of Medicine, University of Cambridge, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
RBR Busch
R Busch
YKY Kim
Y Kim
RNR Neese
R Neese
VSV Schadeserin
V Schadeserin
MCM Collins
M Collins
LML Misell
L Misell

21 November 2007 in Nature Protocols
Verified
Journal Article
Closed access
RBRobert Busch
Robert Busch
RNRichard A Neese
Richard A Neese
MAMohamad Awada
Mohamad Awada
GHGregory M Hayes
Gregory M Hayes
MHMarc K Hellerstein
Marc K Hellerstein

23 September 2005 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
RBRobert Busch
Robert Busch
CRCornelia H. Rinderknecht
Cornelia H. Rinderknecht
SRSujin Roh
Sujin Roh
ALAndrew W. Lee
Andrew W. Lee
JHJames J. Harding
James J. Harding
EMElizabeth Mellins
Elizabeth Mellins

1 November 1998 in Immunity
Verified
Journal Article
Open access
JRJoshua D. Rabinowitz
Joshua D. Rabinowitz
MVMarija Vrljic
Marija Vrljic
PKPeter M. Kasson
Peter M. Kasson
MLMichael N. Liang
Michael N. Liang
RBRobert Busch
Robert Busch
HMHarden M. McConnell
Harden M. McConnell
Peptide binding to class II MHC proteins occurs in acidic endosomal compartments following dissociation of class II-associated invariant chain peptide (CLIP). Based on peptide binding both to empty class II MHC and to molecules preloaded with peptides including CLIP, we find evidence for two isomeric forms of empty MHC. One (inactive) does not bind peptide. The other (active) binds peptide rapidly, with k(on) 1000-fold faster than previous estimates. The active isomer can be formed either by slow isomerization of the inactive molecule or by dissociation of a preformed peptide/MHC complex. In the absence of peptide, the active isomer is unstable, rapidly converting to the inactive isomer. These results demonstrate that fast peptide binding is an inherent property of one isomer of empty class II MHC. Dissociation of peptides such as CLIP yields this transient, peptide-receptive isomer.

1 October 2000 in Immunity
Verified
Journal Article
Open access
RDRobert C. Doebele
Robert C. Doebele
RBRobert Busch
Robert Busch
HSHyman M. Scott
Hyman M. Scott
APAchal Pashine
Achal Pashine
EMElizabeth Mellins
Elizabeth Mellins
HLA-DM removes CLIP and other loosely bound peptides from MHC class II molecules. The crystal structures of class II molecules and of HLA-DM have not permitted identification of their interaction sites. Here, we describe mutations in class II that impair interactions with DM. Libraries of randomly mutagenized DR3 alpha and beta chains were screened for their ability to cause cell surface accumulation of CLIP/DR3 complexes in EBV-B cells. Seven mutations were associated with impaired peptide loading in vivo, as detected by SDS stability assays. In vitro, these mutant DR3 molecules were resistant to DM-catalyzed CLIP release and showed reduced binding to DM. All mutations localize to a single lateral face of HLA-DR, which we propose interacts with DM during peptide exchange.

15 August 1991 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
RBR Busch
R Busch
CHC M Hill
C M Hill
JHJohn Hayball
John Hayball
JLJ R Lamb
J R Lamb
JRJ B Rothbard
J B Rothbard
Class I and class II MHC glycoproteins are highly polymorphic molecules that bind antigenic peptides and present them on cell surfaces for recognition by T lymphocytes. Even though MHC polymorphism has long been known to affect both peptide binding and recognition by the TCR, the role of individual amino acids of MHC proteins in these interactions is poorly understood. To examine the effect of a small number of amino acid residues on T cell stimulation, B lymphoblastoid cell lines homozygous for the closely related DR1 subtypes, Dw1 and Dw20, and the DR4 subtypes, Dw4 and Dw14, were compared for their ability to present an immunogenic influenza hemagglutinin peptide (HA307-319) to an Ag-specific, DR1,4-restricted T cell clone. B cell lines expressing DR1 Dw20 and DR4 Dw14 presented HA307-319 much less efficiently than DR1 Dw1 and DR4 Dw4 and bound a biotinylated analogue of the same peptide less well. Analysis of DRB1 gene sequences suggested that polymorphism at residue 86 had a major effect on peptide binding. Differences in binding of a set of HA307-319 analogues biotinylated at each residue to cells expressing DR1 Dw1 and DR1 Dw20 suggested that the polymorphism affected the interactions of many peptide residues with the class II molecule. In inhibition assays, DR1 Dw1 and DR4 Dw4 were shown to differ from DR1 Dw20 and DR4 Dw14 in their length requirements for peptide binding. Using a larger panel of homozygous B cell lines expressing many class II haplotypes, a Ser-309 substituted HA307-319 analogue was shown to bind to most B cell lines expressing Val-86 containing alleles (including DR1 Dw20 and DR4 Dw14) but failed to bind most B cell lines expressing Gly-86 alleles (including DR1 Dw1 and DR4 Dw4). The results indicated that polymorphism at residue 86 influenced the specificity and affinity of peptide binding and affected the conformation of peptide-DR protein complexes without completely eliminating T cell recognition.